



Denali Therapeutics to Report Third Quarter 2026 Financial Results and Business Highlights on November 3, 2026

October 22, 2026

SOUTH SAN FRANCISCO, Calif., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI) today announced that it will report financial results and business highlights for the third quarter ended September 30, 2026, on Tuesday, November 3, 2026.

Denali's management will host a conference call and webcast on Tuesday, November 3, 2026, at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss third quarter 2026 financial results and provide a general business update.

The live webcast, along with a slide presentation, may be accessed through the Investors section of Denali's website at www.denalitherapeutics.com or by clicking [here](#). A replay of the webcast will be archived on Denali's website for a limited time following the call.

About Denali Therapeutics

Denali Therapeutics Inc. is a biotechnology company pioneering a new class of biotherapeutics designed to cross the blood-brain barrier (BBB) using its proprietary TransportVehicle™ platform. With the first FDA-approved biologic specifically designed to cross the BBB, a clinically validated delivery platform and a growing portfolio of therapeutic candidates across all stages of development, Denali is advancing toward its goal of delivering effective medicines to transform life for people with neurodegenerative diseases, lysosomal storage disorders and other serious diseases. For more information, please visit www.denalitherapeutics.com.

Investor Contact:

Laura Hansen

hansen@dnli.com



Source: Denali Therapeutics Inc.